19
Everest Medicines
1952.HK·HKEXShanghai CNFounded 2017500 employees
Small CapbiotechPublicOncologyNephrology
Platform: CN In-license
Market Cap
$0.8B
All Drugs
2
Clinical Trials
3
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (1952.HK)
Loading 1952.HK stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sotosacituzumab | 195-5047 | Phase 2/3 | 1 | AuroraA | PTSDUrothelial Ca | ||
| 195-4808 | 195-4808 | Preclinical | 2 | TIM-3 | HCCALS |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Everest Medicines trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)